Qual é o preço para Neumora Therapeutics, Inc. Common Stock (NMRA)

O preço para Neumora Therapeutics, Inc. Common Stock (NMRA) é $1.35

Qual é a capitalização de mercado para Neumora Therapeutics, Inc. Common Stock (NMRA)

A capitalização de mercado para Neumora Therapeutics, Inc. Common Stock (NMRA) é $249.21M

Neumora Therapeutics, Inc. Common Stock (NMRA) LPA

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Ano	EPS	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

EPS

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	EPS	Diferença de EPS	País
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$-5.29	-	AU
Lonza Group AG LONN.SW	-	-	CH

Empresa

EPS

Diferença de EPS

País